Eledon Pharmaceuticals (2TK) Stock Statistics & Valuation Metrics
Total Valuation
Eledon Pharmaceuticals has a market cap or net worth of EUR 200.87M. The enterprise value is EUR 398.44M.
- Market Cap
- EUR 200.87M
- Enterprise Value
- EUR 398.44M
Share Statistics
Eledon Pharmaceuticals has 81,261,154 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 81,261,154
- Owned by Insiders
- 0.34%
- Owned by Institutions
- 0.48%
Financial Efficiency
Eledon Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -55.12%.
- Return on Equity (ROE)
- -0.56
- Return on Assets (ROA)
- -0.27
- Return on Invested Capital (ROIC)
- -55.12%
- Return on Capital Employed (ROCE)
- -0.55
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.38M
- Employee Count
- 33
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Eledon Pharmaceuticals is -2.80. Eledon Pharmaceuticals’s PEG ratio is 0.00.
- PE Ratio
- -2.80
- PS Ratio
- 0.00
- PB Ratio
- 4.37
- Price to FCF
- -3.05
- Price to Operating Cash Flow
- -4.26
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Eledon Pharmaceuticals had revenue of 0 and earned -45.62M in profits. Earnings per share was -0.56.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -83.25M
- Pretax Income
- -45.58M
- Net Income
- -45.62M
- EBITDA
- -45.27M
- Earnings Per Share (EPS)
- -0.56
Cash Flow
In the last 12 months, operating cash flow was -73.86M and capital expenditures 0, giving a free cash flow of -73.86M billion.
- Operating Cash Flow
- -73.86M
- Free Cash Flow
- -73.86M
- Free Cash Flow per Share
- -0.65
Dividends & Yields
Eledon Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -32.81%
- Earnings Yield
- -31.31%
Stock Price Statistics
- Beta
- 0.96
- 52-Week Price Change
- -27.37%
- 50-Day Moving Average
- 2.31
- 200-Day Moving Average
- 2.64
- Relative Strength Index (RSI)
- 68.77
- Average Volume (3m)
- 617
Important Dates
Eledon Pharmaceuticals upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Eledon Pharmaceuticals as a current ratio of 7.40, with Debt / Equity ratio of 0.79%
- Current Ratio
- 7.40
- Quick Ratio
- 7.40
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.49
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Eledon Pharmaceuticals has paid 35.00K in taxes.
- Income Tax
- 35.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Eledon Pharmaceuticals EV to EBITDA ratio is -2.70, with an EV/FCF ratio of -2.96.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.70
- EV to Free Cash Flow
- -2.96
- EV to Operating Cash Flow
- -2.96
Balance Sheet
Eledon Pharmaceuticals has EUR 88.76M in cash and marketable securities with EUR 467.00K in debt, giving a net cash position of EUR 88.29M billion.
- Cash & Marketable Securities
- EUR 88.76M
- Total Debt
- EUR 467.00K
- Net Cash
- EUR 88.29M
- Net Cash Per Share
- EUR 1.09
- Tangible Book Value Per Share
- EUR 0.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Eledon Pharmaceuticals is EUR 7.77, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 7.77
- Price Target Upside
- 198.92% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -1945.00%
Scores
- Smart Score
- 6
- AI Score
- ―